Trial Profile
A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Pharmacodynamics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 30 Jul 2022 This trial has been discontinued in Belgium (Date of the global end of the trial : 08-Sep-2021), according to European Clinical Trials Database record.
- 02 Dec 2016 This trial has been completed in France (end date: 7 Aug 2016).
- 16 Mar 2016 New trial record